Back to Atlas
APotentially durableResearch-only / high verification need
CMP-0035
Research tool
Convallatoxin
Senolytic / Cardiac glycoside
Preclinical senolytic candidate
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Cardiac glycoside
- Primary mechanism
- Na+/K+-ATPase inhibition
- Primary market use
- Senolytic research
Pharmacology
- Molecular weight (Da)
- 550.64
- Oral bioavailability
- Oral data not well established
- Half-life
- ~1–12 h provisional PK estimate
- Route tags
- Route-dependent / verify
- Evidence level
- Preclinical
- Clinical status
- Research tool
- Value-for-money score
- 1 / 10
Reported protocol signal
No popular protocol verified yet; keep as reference compound until protocol signal is added.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
Potent cardiac glycoside; toxicity prevents wellness positioning